Online inquiry

IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7151MR)

This product GTTS-WQ7151MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CTGF gene. The antibody can be applied in Hepatic fibrosis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001901.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1490
UniProt ID P29279
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7151MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15369MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ3031MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ15795MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ6015MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ10324MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ4216MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ10280MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LFG 316
GTTS-WQ8706MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW